Twist Bioscience director sells 500 shares

Twist Bioscience Corp director Melissa A. Starovasnik sold 500 shares of Common Stock in an open-market transaction.

Rhea-AI Filing Summary

Twist Bioscience Corp director Melissa A. Starovasnik sold 500 shares of Common Stock in an open-market transaction. The sale occurred on May 26, 2026 at a price of $61.04 per share. After this transaction, she continues to hold 24,722 shares directly. The company notes that this trade was carried out under a previously adopted Rule 10b5-1 trading plan, indicating it was pre-scheduled rather than a discretionary market-timing decision.

Insider Trade Summary 10b5-1

Net Seller: 500 shares

Net Sell 1 txn

Insider Starovasnik Melissa A.

Role Director

Sold 500 shs ($31K)

Type	Security	Shares	Price	Value
Sale	Common Stock	500	$61.04	$31K

Holdings After Transaction: Common Stock — 24,722 shares (Direct)

Footnotes (1)

1. F1. The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on November 22, 2025.

Key Figures

Shares sold: 500 shares Sale price: $61.04 per share Shares held after transaction: 24,722 shares +2 more

5 metrics

Shares sold 500 shares Open-market sale on May 26, 2026

Sale price $61.04 per share Common Stock transaction price

Shares held after transaction 24,722 shares Director’s direct holdings post-sale

Form type Form 4 Insider open-market sale disclosure

Trading plan adoption date November 22, 2025 Rule 10b5-1 plan governing this sale

Key Terms

Rule 10b5-1 trading plan, open-market sale, Form 4, Common Stock

4 terms

Rule 10b5-1 trading plan regulatory

"transactions were effected pursuant to a Rule 10b5-1 trading plan previously adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"The transactions reported on this Form 4 were effected"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Common Stock financial

"security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Twist Bioscience (TWST) report on this Form 4?

Twist Bioscience reported that director Melissa A. Starovasnik sold 500 shares of Common Stock. The open-market transaction was executed at a price of $61.04 per share on May 26, 2026, and was made under a pre-established Rule 10b5-1 trading plan.

At what price were the Twist Bioscience (TWST) shares sold by the director?

The 500 Twist Bioscience shares were sold at $61.04 per share. This price reflects the execution level for the reported open-market transaction on May 26, 2026, as disclosed in the Form 4 insider trading report for director Melissa A. Starovasnik.

How many Twist Bioscience (TWST) shares does the director hold after the sale?

After selling 500 shares, director Melissa A. Starovasnik holds 24,722 Twist Bioscience Common Stock shares directly. This post-transaction holding figure comes from the Form 4 and shows her remaining ownership position immediately following the May 26, 2026 sale.

Was the Twist Bioscience (TWST) insider sale made under a Rule 10b5-1 plan?

Yes. The Form 4 states the transactions were effected under a Rule 10b5-1 trading plan adopted on November 22, 2025. Such plans pre-schedule trades, indicating the timing of this May 26, 2026 sale was arranged in advance rather than decided opportunistically.

Who is the insider involved in the latest Twist Bioscience (TWST) Form 4 filing?

The insider is Melissa A. Starovasnik, a director of Twist Bioscience Corp. She reported an open-market sale of 500 Common Stock shares at $61.04 per share, with 24,722 shares remaining in her direct ownership after the May 26, 2026 transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/28/2026 - 04:05 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Starovasnik Melissa A.

(Last) (First) (Middle)

C/O TWIST BIOSCIENCE CORPORATION

681 GATEWAY BOULEVARD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/26/2026		S(1)		500	D	$61.04	24,722	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on November 22, 2025.

Remarks:

	/s/ Kendra Fox, as Attorney-in-Fact for Melissa A. Starovasnik	05/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)